DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/fq8k8z/investigation) has announced the addition of the "Investigation Report on China's Ossotide Market, 2010-2019" report to their offering.
According to statistics, the incidence of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. Apart from RA, osteoarthritis, an expression of degraded joint function, is also common to see. With the ageing population in China, over 60% of elder people aged above 60 suffer from osteoarthritis, says a study. Patients with osteoarthritis typically show reduced mobility and life quality caused by joint pain, malformation and joint dysfunction.
Ossotide can not only regulate bone metabolism, stimulate osteoblast proliferation, accelerate new bone formation but also regulate calcium-phosphorus metabolism, increase calcium deposits so as to prevent osteoporosis. Ossotide injection and compound ossotide injection was first developed by Nanjing Xinbai Pharmaceutical Co., Ltd which was formerly Nanjing Biochemical Pharmaceutical Factory. In recent years, compound ossotide injection market has shown increasingly fierce competition as it is going from short supply to oversupply, from huge profits to meager profit. Besides, the rise in raw material price has stressed the profit margins.
After entering China market, ossotide is generally growing despite a decline in 2013 with annual sales value rising from less than CNY 60 million in 2005 to CNY 464 million in 2014 and CAGR during this period reaching over 26%.
According to thes market survey, ossotide in the Chinese market mainly come from Harbin Medisan Pharmaceutical Co., Ltd, ZBD Pharmaceutical, Heilongjiang Jiangshi Pharmaceutical Co., Ltd, among which Harbin Medisan Pharmaceutical Co., Ltd has the largest market share of about 19% for sales value in 2014.
Key Topics Covered:
1 Related Concepts of Ossotide
2 Market Profile of Ossotide in China
3 Survey on Sales Status of Ossotide in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Ossotide in China, 2010-2014
5 Survey on Dosage Forms of Ossotide in China, 2010-2014
6 Reference Price of Ossotide in Chinese Hospitals in 2014
7 Major Manufacturers of Ossotide in Chinese Market, 2010-2014
8 Market Outlook of Ossotide in China, 2015-2019
- Harbin Sanctity Pharmaceutical Co., Ltd
- Harbin Medisan Pharmaceutical Co., Ltd
- Heilongjiang Jiangshi Pharmaceutical Co., Ltd
- Harbin Songhe Pharmaceutical Co., Ltd
- Kaifeng Canon Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/fq8k8z/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets